All's well that ends well? Long-term course of a patient with anti-amphiphysin associated limbic encephalitis.
Amnesia
Anti-amphiphysin associated limbic encephalitis
Autoimmune epilepsy
Behavior
Long-term outcome
Journal
Epilepsy & behavior reports
ISSN: 2589-9864
Titre abrégé: Epilepsy Behav Rep
Pays: United States
ID NLM: 101750909
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
09
2021
revised:
08
03
2022
accepted:
09
03
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Anti-amphiphysin associated limbic encephalitis (LE) is a paraneoplastic autoimmune disorder. The initial clinical presentation features seizures, cognitive and neuropsychiatric symptoms. We present the case of a 25-year-old female patient hospitalized after four consecutive tonic-clonic seizures, followed by confusion, psychotic symptoms, nonconvulsive seizure series, and severe global amnesia. Diagnostic workup revealed anti-amphiphysin associated LE without a tumor. MRI and PET indicated inflammatory processes affecting the bilateral mesial temporal structures more pronounced on the left side. Antiseizure medication, benzodiazepines, and immunotherapy resulted in rapid seizure cessation. Subsequent MRI and PET indicated left hippocampal sclerosis and a left mesial temporal hypometabolism. Executive dysfunction resolved in the following weeks. Global amnesia persisted for almost three months. Two years later, episodic memory was normal with residual visual memory impairments. While this patient's seizure and cognitive outcome has been favorable, behavioral problems persisted long after disease onset. The persisting behavioral problems and subsequent MRI evidence (13 years after onset) of a swollen right amygdala indicated a possible relapse. This case report illustrates the importance of early diagnosis of LE for best clinical management. Antiseizure medication and immunotherapy led to seizure freedom and almost complete recovery of cognition. However, long-lasting neuropsychiatric symptoms and possible recurrent inflammation highlight the need for a multimodal long-term monitoring of such patients to rule out a relapse.
Identifiants
pubmed: 35360257
doi: 10.1016/j.ebr.2022.100534
pii: S2589-9864(22)00011-9
pmc: PMC8960971
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100534Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest with regard to the current work. J. Taube has nothing to disclose; Dr. Witt reports personal fees from Eisai, outside the submitted work; Dr. Baumgartner reports personal fees from Eisai and UCB, outside the submitted work; Prof. Dr. Helmstaedter reports personal fees from Precisis, Eisai, UCB, and GW, outside the submitted work.
Références
J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):387-91
pubmed: 24403282
J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):735-42
pubmed: 25185210
Ann Neurol. 2005 Jul;58(1):96-107
pubmed: 15984030
Eur J Neurol. 2013 Sep;20(9):1297-304
pubmed: 23678940
Neurology. 2016 Oct 4;87(14):1449-1456
pubmed: 27590293
Neurology. 2021 Sep 14;97(11):e1141-e1149
pubmed: 34233939
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Epilepsy Behav. 2018 Dec;89:105-111
pubmed: 30408704
J Neuroimmunol. 2014 Sep 15;274(1-2):209-14
pubmed: 25087755
BMC Neurosci. 2010 Sep 16;11:118
pubmed: 20846444
Arch Clin Neuropsychol. 2006 Aug;21(5):413-20
pubmed: 16843636
Brain Res. 2018 Dec 15;1701:146-152
pubmed: 30205110
Epilepsia. 2013 Sep;54(9):1679-87
pubmed: 23889589
Epilepsy Behav. 2019 Nov;100(Pt A):106516
pubmed: 31574430
Brain Sci. 2021 Apr 29;11(5):
pubmed: 33947002
Acta Neuropsychiatr. 2020 Aug;32(4):177-185
pubmed: 31791436
J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):214-7
pubmed: 10071102
Front Neurol. 2015 Aug 03;6:167
pubmed: 26284025